This gain-of-function of ALAS2 increases protoporphyrin IX production in the context of normal FECH activity, the latter of which becomes rate-limiting and presumably leads to the onset of the EPP-like disease phenotype. Here, ALAS2 is linked to autosomal erythropoietic protoporphyria.